Health Topics — Women's Health
Hormones, Stress, and Why They Won't Leave Each Other Alone
For the woman whose stress and hormonal symptoms arrive together and resist being treated separately — what the research shows about why that is.
You may have noticed a pattern. Your anxiety is worse in the days before your period. Your sleep falls apart when work stress peaks, and your cycle becomes irregular when it does. The mood that arrives mid-cycle, or the tension that spikes before bleeding begins, doesn't feel like a coincidence — and it isn't. Stress and hormonal health are not separate systems that occasionally interfere with each other. They are the same system, running in both directions at once.
The body has two great hormonal command systems. The HPA axis — the hypothalamus-pituitary-adrenal axis — governs the stress response and cortisol production. The HPG axis — the hypothalamus-pituitary-gonadal axis — governs reproductive hormones: estrogen, progesterone, testosterone. Both originate in the same structure of the brain, the hypothalamus, and both respond to signals from the same stress-sensing systems. When one is activated, it affects the other. This is not coincidence. It is architecture.
Chronic stress — the kind that becomes a baseline rather than a response — activates the HPA axis persistently. Cortisol stays elevated. And elevated cortisol has documented effects on reproductive hormonal health: it suppresses the pulsatile release of GnRH, the signal that drives estrogen and progesterone production. In plain terms, chronic stress tells the body that this is not the right time to allocate resources to reproduction — and the body listens, at the expense of the hormonal balance that supports mood, sleep, cycle regularity, and pain sensitivity.
The compounding pattern — and why it feels impossible to break
Cortisol suppresses estrogen and progesterone. Lower estrogen means lower anandamide — because estrogen directly supports the endocannabinoid system's ability to produce and preserve this regulatory molecule. Lower anandamide means less of the body's own capacity to regulate mood, stress response, and pain sensitivity. And less of that regulatory capacity means the body handles the next stress event less well — which means cortisol rises again, and the cycle continues.
This is why trying to address stress and hormonal symptoms separately is so often frustrating. They are not separate problems that happen to co-occur. They are a single biological loop, feeding itself. Treating the anxiety without addressing the hormonal context, or addressing the hormonal symptoms without addressing the chronic stress load, leaves the underlying pattern intact.
For women, this loop has a particular texture. The pre-menstrual window — when progesterone is dropping and estrogen is following it — is the point in the cycle where endocannabinoid tone is naturally lowest. If cortisol is also elevated from a sustained stress load, the regulatory capacity available during that window is doubly reduced. This is why pre-menstrual anxiety, mood disruption, and sleep difficulty often feel more severe during periods of external stress. The biology makes it so.
Where the endocannabinoid system and CBG research connect
The endocannabinoid system sits at the intersection of these two axes. CB1 receptors in the hypothalamus — the origin point of both the HPA and HPG axes — play a documented role in moderating cortisol release after a stress event. When the endocannabinoid system is functioning well, it helps terminate the cortisol response — turning off the stress signal after the threat has passed. When it isn't functioning well, cortisol stays elevated longer than it should, with downstream consequences for hormonal health.
CBG's most relevant research in this context is the 2024 Cuttler human trial — the first randomized controlled study of CBG in healthy adults, which found statistically significant reductions in self-reported anxiety and stress compared to placebo following a single oral dose. Because the HPA-HPG connection means that anything genuinely reducing the stress response has potential relevance to hormonal health through that upstream pathway, this research is relevant here even though it was not conducted in a hormonal health population specifically.
CBD's relevant mechanism is FAAH inhibition — slowing the breakdown of anandamide and supporting its availability. In the pre-menstrual window when anandamide is naturally lowest and estrogen-driven support for its production is minimal, this mechanism is directly relevant. It addresses the depletion pattern that makes this particular hormonal window so difficult for many women.
On what the research shows and doesn't show
No human trial has tested CBG or CBD specifically for the stress-hormonal interaction described in this article. The Cuttler CBG trial establishes a stress-reducing signal. The CBD-anandamide mechanism is established in laboratory research. The connection between stress, cortisol, and hormonal health is among the most documented findings in endocrinology.
The mechanistic picture is coherent and well-founded. The clinical evidence specifically in this population and for this interaction is still developing.
What this means in practice
We can't tell you that a CBG or CBD preparation will resolve the stress-hormonal loop. What we can say is that the loop has documented biology — it is not a coincidence or a perception — and that the endocannabinoid system is specifically present at its intersection in ways that make cannabinoid research in this area scientifically motivated rather than speculative.
If you're considering a whole-plant cannabinoid preparation in the context of the stress-hormonal pattern described here, the most relevant approach is consistent use over time rather than targeted use at particular points in the cycle — because the regulatory capacity of the endocannabinoid system builds through consistent support, not through acute intervention.
Future articles in this pillar examine the specific research on cortisol and the stress response, the estrogen-ECS interaction in detail, and what the Cuttler CBG trial found specifically about stress in a female population. If you want the fuller picture now, the research section is the place to start.
Stress and hormonal symptoms that arrive together are not two problems — they are one biology, running in both directions. The endocannabinoid system is at the center of that biology in ways that are documented and specific. The research on CBG and the stress response, and on CBD and anandamide availability, connects to this picture in ways worth understanding. We will follow the evidence as it develops. In the meantime, you deserve an honest account of what the research shows — and that is what this archive is for.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.